How Glaucoma Treatment Benefits From Big Data and MIGS
Glaucoma can damage the optic nerve long before a person notices changes in their vision. Because early disease may have few noticeable symptoms, ophthalmologists need reliable ways to assess risk, monitor progression, and choose treatments that fit each patient’s needs.
At the American Academy of Ophthalmology (AAO) 2026 annual meeting, specialists discussed how large health datasets and minimally invasive glaucoma surgery (MIGS) could help improve clinical decisions. The session, reported by The American Journal of Managed Care (AJMC) on October 11, 2026, explored both population-level evidence and the challenges of selecting surgical procedures for individual patients.
The discussion highlighted two complementary approaches: using real-world health information to understand glaucoma patterns and choosing surgical techniques according to a patient’s disease severity, medical history, and treatment needs.
How Big Data Helps Ophthalmologists Understand Glaucoma
Large health datasets allow researchers to examine information from enormous numbers of patients. These records can reveal patterns that would be difficult to identify through individual clinical encounters or small research studies alone.
Victoria Tseng, MD, PhD, an assistant professor in residence and Jerome and Joan Snyder Chair in Ophthalmology at the UCLA Stein Eye Institute, discussed the role of big data during the AAO 2026 session. She described how existing datasets can help researchers investigate glaucoma risk factors, differences in access to care, and treatment outcomes.
Two resources discussed during the session were the American Academy of Ophthalmology’s IRIS Registry and the UK Biobank. The IRIS Registry focuses on ophthalmic clinical information, while the UK Biobank contains broader health data that researchers can use to investigate relationships between eye conditions and general health.
Depending on the dataset, information may include electronic health records, eye imaging, demographic characteristics, and social determinants of health. Combining these sources can help researchers identify patterns that might otherwise remain difficult to detect.
For example, the data discussed at the meeting linked physical activity with a lower risk of glaucoma. Diet was also identified as a potentially relevant factor, while substance use was associated with a greater likelihood of elevated intraocular pressure (IOP).
These findings should be interpreted carefully. Associations observed in large datasets do not automatically establish that a particular behavior causes or prevents glaucoma, and individual risk depends on multiple clinical factors.
Why Health Equity Matters in Glaucoma Care
Glaucoma outcomes depend on more than the medical treatment selected. Access to eye examinations, diagnostic testing, specialist appointments, and follow-up care can also influence when the condition is detected and how it is managed.
During the AAO session, Tseng discussed research using the Social Vulnerability Index to examine connections between community deprivation and glaucoma outcomes. Studies cited in the presentation found that patients living in areas experiencing greater deprivation had more advanced glaucoma when diagnosed and underwent more glaucoma surgery.
The presentation also highlighted differences in care among racial and ethnic groups. Analyses of health records found that Black and Hispanic beneficiaries received fewer ancillary tests and attended fewer eye care visits than some comparison groups.
These findings identify potential gaps in access and care delivery, rather than proving that every patient in a particular demographic group experiences the same circumstances. They also demonstrate why demographic and socioeconomic information can be important when evaluating the quality of health services.
For healthcare systems, this type of evidence may help identify communities where earlier detection, better appointment access, or more consistent monitoring deserves attention. Researchers can then investigate which interventions are most effective at reducing disparities.
Large datasets can also strengthen knowledge about rare eye diseases by bringing together information from patients treated in different locations. This broader evidence base may help specialists recognize unusual presentations and evaluate possible management approaches when individual clinicians have limited experience with a condition.
What MIGS Means for Patients With Glaucoma
Minimally invasive glaucoma surgery refers to procedures designed to lower eye pressure using relatively small surgical interventions. These techniques can be considered for selected patients, including some people undergoing cataract surgery who also need treatment for glaucoma.
The goal is to reduce intraocular pressure, a major modifiable risk factor for glaucoma progression. The most appropriate procedure depends on the patient’s disease severity, eye anatomy, previous treatments, pressure targets, and other clinical considerations.
During the AAO 2026 session, Jella An, MD, MBA, a professor of ophthalmology at the Storm Eye Institute of the Medical University of South Carolina, presented a clinical case illustrating why surgical decisions cannot follow a single formula.
The patient was a 77-year-old Black man referred for cataract surgery who was also being monitored for primary open-angle glaucoma. He had difficulty consistently following his prescribed medication regimen, and visual field testing showed severe damage in the right eye and moderately severe damage in the left.
For the left eye, An considered a MIGS procedure appropriate, including a stent-based approach intended to preserve the trabecular meshwork, a structure involved in draining fluid from the eye. The right eye presented a more complex situation because the glaucoma was more advanced.
For that eye, the surgical approach combined lens removal, canaloplasty, placement of a Hydrus stent, and implantation of a travoprost implant. The reported outcome was successful, with the patient achieving 20/25 vision.
This case demonstrates how specialists may consider different approaches for each eye of the same patient. It does not establish that the same combination is suitable for everyone with glaucoma or that a similar visual result can be expected in other patients.
Why One Glaucoma Procedure May Not Be Enough
Glaucoma is a long-term condition, and treatment must be tailored to the amount of existing damage and the risk of further vision loss. Although MIGS can offer benefits for appropriately selected patients, its suitability depends on the clinical circumstances.
Some patients may benefit from a single procedure, while others may require a combination of surgical techniques or additional treatment. More advanced disease can create challenges that cannot necessarily be addressed with a conventional MIGS procedure alone.
Medication adherence is another important consideration. When patients struggle to follow an eye-drop regimen, clinicians may discuss whether a different treatment strategy could help maintain pressure control. However, surgical treatment does not automatically eliminate the need for medication or ongoing monitoring.
Doctors typically assess glaucoma through several methods, including tonometry to measure intraocular pressure, visual field testing to evaluate functional vision, optic nerve examination, and imaging of the retinal nerve fiber layer. Gonioscopy may also be used to examine the drainage angle and help determine which procedures are appropriate.
These examinations provide different pieces of information. A pressure measurement alone cannot establish the full extent of glaucoma damage, which is why treatment decisions generally consider multiple clinical findings.
When to See an Eye Doctor and What to Ask
Glaucoma may progress without obvious warning signs, particularly during its early stages. Adults with risk factors such as older age, a family history of glaucoma, or other relevant medical considerations should discuss an appropriate screening schedule with an eye care professional.
Seek urgent medical attention if you experience sudden severe eye pain, a red eye accompanied by blurred vision, halos around lights, or a sudden headache with nausea or vomiting. These symptoms can indicate acute angle-closure glaucoma or another eye emergency and should not be ignored.
For people already diagnosed with glaucoma, regular follow-up appointments help clinicians monitor pressure, evaluate changes in the optic nerve and visual field, and determine whether treatment remains effective.
Can big data determine the best glaucoma treatment for every patient?
No. Large datasets can reveal useful patterns and support clinical research, but they cannot replace an individual examination. Ophthalmologists must interpret the evidence alongside each patient’s medical history, test results, and treatment goals.
Is MIGS suitable for all people with glaucoma?
No. Suitability depends on disease severity, eye anatomy, the pressure target, and other factors. Some patients may need different procedures or a broader treatment plan, particularly when glaucoma is advanced.
Does glaucoma surgery mean patients can stop using eye drops?
Not necessarily. Some procedures may reduce medication requirements, but the outcome varies. Patients should continue following their prescribed treatment plan unless their ophthalmologist advises otherwise.
The AAO 2026 discussion reinforces the value of combining population-level evidence with individualized treatment decisions. If you have glaucoma or have been told you are at increased risk, schedule an eye examination and ask your ophthalmologist about your current pressure targets, visual field results, and the full range of appropriate treatment options.
